

# Financial Tear Sheet

## Corporate Profile

BrainStorm (NASDAQ:BCLI) is a biotechnology company developing innovative, autologous stem cell therapies for highly debilitating neurodegenerative diseases such as Amyotrophic Lateral Sclerosis (ALS, also known as Lou Gehrig's disease), Multiple Sclerosis (MS) and Parkinson's Disease (PD).

## Stock Information

| BCLI (Common Stock)              |                       |
|----------------------------------|-----------------------|
| Exchange                         | NASDAQ CM (US Dollar) |
| Price                            | \$4.94                |
| Change (%)                       | 0.00 (0.00%)          |
| Volume                           | 13,619                |
| 52 Week Low                      | \$2.06                |
| Market Cap                       | \$92,553,617          |
| Rolling EPS                      | -0.27                 |
| PE Ratio                         | 0                     |
| Shares Outstanding               | 18,735,550            |
| Data as of 07/24/17 9:32 a.m. ET |                       |



Data provided by Nasdaq. Minimum 15 minutes delayed.

## Latest News

July 21, 2017

**BRAINSTORM AWARDED \$16 MILLION  
NON-DILUTIVE GRANT FROM CIRM IN SUPPORT  
OF PHASE 3 CLINICAL TRIAL OF NUROWN® IN  
ALS**

July 18, 2017

**BRAINSTORM ANNOUNCES AGREEMENTS WITH  
MASS. GENERAL HOSPITAL AND CALIFORNIA  
PACIFIC MEDICAL CENTER TO PARTICIPATE IN  
PHASE 3 TRIAL OF NUROWN® IN ALS**

July 3, 2017

**WORLDWIDE CLINICAL TRIALS SELECTED BY  
BRAINSTORM AS CRO FOR PHASE 3 NUROWN  
TRIAL IN ALS**

## SEC Filings

| Filing Date | Form |
|-------------|------|
| 07/21/17    | 8-K  |
| 07/17/17    | 4    |
| 07/17/17    | 4    |
| 05/15/17    | 10-Q |

## Upcoming Events

**BIO INTERNATIONAL CONVENTION**

June 21, 2017 2:00 p.m. PT

**WORLD ADVANCED THERAPIES & REGENERATIVE  
MEDICINE CONGRESS 2017**

May 18, 2017 2:40 p.m. CT

**INTERNATIONAL SOCIETY FOR CELLULAR  
THERAPY ANNUAL CONFERENCE**

May 4, 2017 3:30 p.m. CT

## Primary IR Contact

Michael Rice

LifeSci Advisors LLC

E-mail: [mrice@lifesciadvisors.com](mailto:mrice@lifesciadvisors.com)